{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:52:07Z","timestamp":1794552727675,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Ningbo grants","award":["2022J028"],"award-info":[{"award-number":["2022J028"]}]},{"name":"Natural Science Foundation of Ningbo grants","award":["2022J033"],"award-info":[{"award-number":["2022J033"]}]},{"name":"Zhejiang Province Traditional Chinese Medicine Science and Technology Project","award":["2023ZL685"],"award-info":[{"award-number":["2023ZL685"]}]},{"name":"Ningbo Medical & Health Leading Academic Discipline Project","award":["2022-S05"],"award-info":[{"award-number":["2022-S05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Acute myeloid leukemia (AML) is associated with high rates of resistance to standard therapies, necessitating the exploration of novel treatment strategies. Venetoclax (VEN) has shown efficacy in AML, yet drug resistance remains a significant challenge. This study aims to explore the synergistic effects of combining dihydroartemisinin (DHA) with VEN to improve therapeutic outcomes in AML.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>AML cell lines and primary cells from AML patients were treated with various concentrations of DHA, VEN and their combined regimen. The cytotoxic effects were evaluated using MTS assays, flow cytometry for apoptosis analysis, and cell cycle assessments. Protein levels of caspase-3, PARP, MCL-1, BCL-XL and C-MYC were analyzed to elucidate the underlying mechanisms of the observed synergy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The combination of VEN and DHA demonstrated a significant synergistic cytotoxic effect on AML cells, characterized by reduced cell proliferation, induced apoptosis, and cell cycle arrest in the G0\/G1 phase. Mechanistically, the synergy was associated with increased levels of cleaved caspase-3 and PARP, along with the downregulation of anti-apoptotic proteins MCL-1 and BCL-XL. Additionally, the combined treatment led to a significant decrease in C-MYC expression. This synergistic effect was consistently observed across all primary AML patient samples analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The findings suggest that the combination of VEN and DHA exerts synergistic anti-leukemic effects by targeting BCL-XL, MCL-1 and C-MYC, offering a promising therapeutic strategy for AML.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12672-025-02242-7","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:49:42Z","timestamp":1744206582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC\/BCL-XL\/MCL-1 triple targeting"],"prefix":"10.1007","volume":"16","author":[{"given":"Fenglin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihui","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"3","key":"2242_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326.","journal-title":"Am J Hematol"},{"issue":"1","key":"2242_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"10393","key":"2242_CR3","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, et al. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073\u201386.","journal-title":"Lancet"},{"issue":"5","key":"2242_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(5):503\u201313.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"2242_CR5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.26991","volume":"98","author":"AH Matthews","year":"2023","unstructured":"Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023;98(8):1254\u201364.","journal-title":"Am J Hematol"},{"issue":"8","key":"2242_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/cncr.33477","volume":"127","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Kadia TM, DiNardo CD, et al. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021;127(8):1186\u2013207.","journal-title":"Cancer"},{"issue":"6","key":"2242_CR7","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00277-020-04375-x","volume":"100","author":"K Laribi","year":"2021","unstructured":"Laribi K, Sobh M, Ghez D, et al. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Ann Hematol. 2021;100(6):1359\u201376.","journal-title":"Ann Hematol"},{"issue":"4","key":"2242_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/13543784.2023.2193679","volume":"32","author":"A Bruzzese","year":"2023","unstructured":"Bruzzese A, Martino EA, Mendicino F, et al. Venetoclax in acute myeloid leukemia. Expert Opin Investig Drugs. 2023;32(4):271\u20136.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2242_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Pinto Neto JV, et al. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol. 2018;11(1):65.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2242_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"7","key":"2242_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"2242_CR12","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.blre.2022.101036","volume":"59","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Bates M, Tomasson MH, et al. Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold? Blood Rev. 2023;59:101036.","journal-title":"Blood Rev"},{"issue":"1","key":"2242_CR13","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12935-020-01614-z","volume":"20","author":"X Yue","year":"2020","unstructured":"Yue X, Chen Q, He J. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 2020;20(1):524.","journal-title":"Cancer Cell Int"},{"key":"2242_CR14","doi-asserted-by":"publisher","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","volume":"12","author":"J Liu","year":"2022","unstructured":"Liu J, Chen Y, Yu L, et al. Mechanisms of Venetoclax resistance and solutions. Front Oncol. 2022;12:1005659.","journal-title":"Front Oncol"},{"issue":"35","key":"2242_CR15","doi-asserted-by":"publisher","first-page":"10210","DOI":"10.1002\/anie.201601967","volume":"55","author":"Y Tu","year":"2016","unstructured":"Tu Y. Artemisinin-a gift from traditional Chinese medicine to the world (Nobel Lecture). Angew Chem Int Ed Engl. 2016;55(35):10210\u201326.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"2242_CR16","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2011.08.024","volume":"146","author":"LH Miller","year":"2011","unstructured":"Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell. 2011;146(6):855\u20138.","journal-title":"Cell"},{"issue":"1","key":"2242_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eng.2018.11.011","volume":"5","author":"J Wang","year":"2019","unstructured":"Wang J, Xu C, Wong YK, et al. Artemisinin, the magic drug discovered from traditional Chinese medicine. Engineering. 2019;5(1):32\u20139.","journal-title":"Engineering"},{"issue":"5","key":"2242_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10495-011-0580-6","volume":"16","author":"N Gao","year":"2011","unstructured":"Gao N, Budhraja A, Cheng S, et al. Interruption of the MEK\/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis. 2011;16(5):511\u201323.","journal-title":"Apoptosis"},{"issue":"1","key":"2242_CR19","first-page":"88","volume":"28","author":"YH An","year":"2020","unstructured":"An YH, Du J, Hou ZW, et al. Dihydroartemisinin Induces AML cell apoptosis by inhibition of PTEN\/AKT pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020;28(1):88\u201392.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"1","key":"2242_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.31557\/APJCP.2024.25.1.343","volume":"25","author":"R Nazmabadi","year":"2024","unstructured":"Nazmabadi R, Pooladi M, Amri J, et al. The effects of ABT-199 and Dihydroartemisinin combination on cell growth and apoptosis in human U937 and KG-1 cancer cells. Asian Pac J Cancer Prev. 2024;25(1):343\u201350.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"2242_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12967-023-03968-0","volume":"21","author":"F Li","year":"2023","unstructured":"Li F, Ye W, Yao Y, et al. Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2\/STAT3\/STAT5 axis. J Transl Med. 2023;21(1):115.","journal-title":"J Transl Med"},{"key":"2242_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5531","author":"F Li","year":"2023","unstructured":"Li F, Ling Q, Lian J, et al. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia. Cancer Med. 2023. https:\/\/doi.org\/10.1002\/cam4.5531.","journal-title":"Cancer Med"},{"issue":"5","key":"2242_CR23","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00277-023-05156-y","volume":"102","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, Li F, Xu Y, et al. Loss of IRF8 inhibits the growth of acute myeloid leukemia cells. Ann Hematol. 2023;102(5):1063\u201372.","journal-title":"Ann Hematol"},{"key":"2242_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.freeradbiomed.2018.12.011","volume":"131","author":"J Du","year":"2019","unstructured":"Du J, Wang T, Li Y, et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med. 2019;131:356\u201369.","journal-title":"Free Radic Biol Med"},{"key":"2242_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.bcp.2018.01.031","volume":"150","author":"X Yan","year":"2018","unstructured":"Yan X, Li P, Zhan Y, et al. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation. Biochem Pharmacol. 2018;150:72\u201385.","journal-title":"Biochem Pharmacol"},{"key":"2242_CR26","doi-asserted-by":"publisher","first-page":"27696","DOI":"10.1038\/srep27696","volume":"6","author":"KH Lin","year":"2016","unstructured":"Lin KH, Winter PS, Xie A, et al. Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in Acute Myeloid Leukemia. Sci Rep. 2016;6:27696.","journal-title":"Sci Rep"},{"issue":"17","key":"2242_CR27","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","volume":"22","author":"X Niu","year":"2016","unstructured":"Niu X, Zhao J, Ma J, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with Daunorubicin or Cytarabine in AML cells. Clin Cancer Res. 2016;22(17):4440\u201351.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2242_CR28","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1080\/10428194.2018.1563694","volume":"60","author":"Q Wang","year":"2019","unstructured":"Wang Q, Wan J, Zhang W, et al. MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells. Leuk Lymphoma. 2019;60(9):2170\u201380.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2242_CR29","first-page":"202","volume":"47","author":"R Tang","year":"2021","unstructured":"Tang R, Cheng A, Guirales F, et al. c-MYC Amplification in AML. J Assoc Genet Technol. 2021;47(4):202\u201312.","journal-title":"J Assoc Genet Technol"},{"issue":"2","key":"2242_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2643-3230.BCD-20-0029","volume":"2","author":"S Yun","year":"2021","unstructured":"Yun S, Vincelette ND, Yu X, et al. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discov. 2021;2(2):162\u201385.","journal-title":"Blood Cancer Discov"},{"key":"2242_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106194","volume":"84","author":"S Yun","year":"2019","unstructured":"Yun S, Sharma R, Chan O, et al. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019;84: 106194.","journal-title":"Leuk Res"},{"issue":"11\u201312","key":"2242_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10495-022-01756-7","volume":"27","author":"S Liu","year":"2022","unstructured":"Liu S, Qiao X, Wu S, et al. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis. 2022;27(11\u201312):913\u201328.","journal-title":"Apoptosis"},{"issue":"2","key":"2242_CR33","first-page":"452","volume":"13","author":"B Jeon","year":"2023","unstructured":"Jeon B, Lee YJ, Shin J, et al. A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc\/Bcl-2\/Mcl-1 triple targeting. Am J Cancer Res. 2023;13(2):452\u201363.","journal-title":"Am J Cancer Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02242-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02242-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:49:43Z","timestamp":1744206583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02242-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02242-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of The Affiliated People\u2019s Hospital of Ningbo University. Written informed consent was obtained from all individual participants included in the current study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"496"}}